IRIS
PALLADINI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.018
EU - Europa 3.449
AS - Asia 2.196
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 6
SA - Sud America 4
Totale 10.691
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.000
CN - Cina 2.079
IE - Irlanda 1.470
FI - Finlandia 531
UA - Ucraina 462
DE - Germania 340
SE - Svezia 225
IT - Italia 187
GB - Regno Unito 102
FR - Francia 51
IN - India 38
JP - Giappone 30
BE - Belgio 26
CA - Canada 17
AT - Austria 15
IR - Iran 15
SG - Singapore 11
CZ - Repubblica Ceca 9
MU - Mauritius 9
HK - Hong Kong 7
RU - Federazione Russa 7
AU - Australia 6
EU - Europa 5
GR - Grecia 5
NL - Olanda 5
CL - Cile 4
ES - Italia 4
RO - Romania 4
KR - Corea 3
TR - Turchia 3
DK - Danimarca 2
IL - Israele 2
PK - Pakistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CH - Svizzera 1
EG - Egitto 1
ID - Indonesia 1
IQ - Iraq 1
LU - Lussemburgo 1
LV - Lettonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MX - Messico 1
MY - Malesia 1
PH - Filippine 1
PT - Portogallo 1
SA - Arabia Saudita 1
SL - Sierra Leone 1
ZA - Sudafrica 1
Totale 10.691
Salva come PNG Salva come JPEG
Città #
Dublin 1.470
Chandler 1.325
Jacksonville 659
Nanjing 569
Ashburn 359
Princeton 259
Lawrence 251
Nanchang 249
Medford 238
Helsinki 223
Beijing 220
Wilmington 209
Shenyang 179
Hebei 162
Changsha 156
Ann Arbor 143
Jiaxing 132
Tianjin 104
Shanghai 95
Boardman 92
Hangzhou 90
Woodbridge 64
Piscataway 63
Norwalk 51
Pavia 51
Milan 39
New York 38
Seattle 32
Fairfield 30
Pune 27
Tokyo 27
Brussels 26
Los Angeles 24
Ningbo 22
Verona 22
Des Moines 18
Zhengzhou 18
Houston 17
Kunming 16
Washington 16
Toronto 13
Induno Olona 12
Redwood City 11
Auburn Hills 10
Taizhou 10
Singapore 9
Tamm 9
Bari 8
Brno 8
Falkenstein 8
Jinan 8
Tappahannock 8
Vienna 7
Fuzhou 6
Orange 6
San Francisco 6
Berlin 4
Borås 4
Falls Church 4
Guangzhou 4
Haikou 4
Lanzhou 4
San Genesio Ed Uniti 4
Sydney 4
Tehran 4
Andover 3
Catania 3
Changchun 3
Dearborn 3
Detroit 3
Munich 3
Trino 3
Zanjan 3
Athens 2
Bhubaneswar 2
Birmingham 2
Bologna 2
Cambridge 2
Chignolo d'Isola 2
Fayetteville 2
Gunzenhausen 2
Karachi 2
Kemerovo 2
Las Vegas 2
Latisana 2
London 2
Markham 2
Nabeshima 2
Nagold 2
Novokuznetsk 2
Rockville 2
Sacramento 2
Torino 2
Vinovo 2
Alexandria 1
Altoona 1
Ardabil 1
Baltimore 1
Bloomfield 1
Cairo 1
Totale 8.032
Salva come PNG Salva come JPEG
Nome #
Valore prognostico della presenza di bassi voltaggi elettrocardiografici nei pazienti affetti da amiloidosi AL 89
Autologous stem cell transplantation following heart transplantation for AL amyloidosis 85
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 82
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. 79
Bone marrow amyloidosis. 79
Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis 77
Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. 77
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 76
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 76
Chronic intestinal pseudo-obstruction secondary to al amyloidosis associated with severe gastroparesis: case report 75
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 75
Nutritional status evaluation of patients affected by al amyloidosis: a pilot study 73
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy 73
Bortezomib-induced paralytic ileus is a potential gastrointestinal side-effect of this first-in-class anti-cancer proteasome inhibitor 72
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis 72
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 72
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy 72
Reasoning with Effects of Clinical Guideline Actions Using OWL: AL Amyloidosis as a Case StudyKnowledge Representation for Health-Care 72
Liver biopsy discloses a new apolipoprotein AI hereditary amyloidosis in several unrelated Italian families 71
Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis 68
Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide 67
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 66
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 66
Light chain amyloidosis 2012: a new era. 65
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 65
Clotting alterations in primary systemic amyloidosis. 64
Amyloid typing: immunoelectron microscopy 64
Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis 64
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 64
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 63
Comment on: parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren's Syndrome. 63
Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome. 63
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 63
Holter monitoring in AL amyloidosis: prognostic implications. 62
Biochemical markers in early diagnosis and management of systemic amyloidoses 62
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 62
Analysis of Vlambda-Jlambda expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambda III) as a new amyloid-associated germline gene segment 62
Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in- class anticancer proteasome inhibitor. 62
Clinical aspects of systemic amyloid diseases. 61
A novel approach for the purification and proteomic analysis of pathogenic immunglobulin free light chains from serum 61
Abnormalities in thrombin-antithrombin pathway in primary systemic amyloidosis. 61
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis 61
Dieta a contenuto controllato di proteine in pazienti affetti da amiloidosi AL con coinvolgimento renale 60
Structural features of two monoclonal cryocrystalglobulins causing a rheumatic syndrome with vasculitis. 58
Unusual manifestations of disseminated neoplasia at presentation: right-sided heart failure due to a massive cardiac metastasis and autoimmune thrombocytopenia in pleomorphic rhabdomyosarcoma of the adult. 58
The association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis ineligible for stem cell transplantation 58
Sjögren’s syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity? 58
A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. 58
AMICA: an electronic patient record specifically designed for an amyloidosis network. 58
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 58
The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44 58
End-stage renal failure due to amyloidosis and recurrent fever on dialysis--is there a link? 57
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 57
Amyloid diseases at the molecular level: general overview and focus on AL amyloidosis. 57
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue 57
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective 57
Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis 56
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 56
Bortezomib in a Phase 1 Trial for Patients with Relapsed AL Amyloidosis: Cardiac Responses and Overall Effects 56
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes 56
Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. 56
Treating advanced cardiac damage in light chain amyloidosis: still an unmet need 56
First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome 56
Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans 56
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 56
A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin in primary amyloidosis (AL) 55
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 55
A patient with AL amyloidosis with negative free light chain results 55
Cardiac light chain amyloidosis: The role of metal ions in oxidative stress and mitochondrial damage 55
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib and dexamethasone 54
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 54
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis 54
Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis 54
Light chain amyloidosis: the heart of the problem 53
Prevalence and Prognostic Value of Conduction Disturbances at the Time of Diagnosis of Cardiac AL Amyloidosis 53
AMICA: an electronic patient record specifically designed for an amyloidosis network 53
Uniform risk-stratification and response criteria are paving the way to evidence-based treatment of AL amyloidosis 52
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis 52
Ovarian hyperstimulation syndrome in systemic amyloidosis 52
Diagnostic and Prognostic Value of Low QRS Voltages in Cardiac AL Amyloidosis 52
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E-coli 52
Protein Aggregation 52
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 52
Therapy and management of systemic AL (primary) amyloidosis 51
Bortezomib in the treatment of AL amyloidosis: targeted therapy? 51
Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. 51
In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study 51
Enlightening light chain deposition disease 51
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 51
Thalidomide plus intermediate-dose dexametasone is an effective but toxic treatment for patients with AL (primary) amyloydosis 51
Valore prognostico della presenza di disturbi della conduzione cardiaca nei pazienti affetti da amiloidosi AL 50
Renal involvement in systemic amyloidosis 50
Structural features of two monoclonal cryocrystalglobulins causing a rheumatic syndrome with vasculitis 50
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 49
Renal involvement in systemic amyloidosis--an Italian retrospective study on epidemiological and clinical data at diagnosis 49
Insights into the regulation of immunoglobulin light chain gene rearrangements via analysis of the kappa light chain locus in lambda myeloma 49
Current treatment of AL amyloidosis 49
Hepatic amyloidosis with light chain deposition disease. A rare association. 49
Systemic amyloidoses: what an Internist should know 49
La rilevanza diagnostica e prognostica del peptide natriuretico di tipo B (BNP) e del suo frammento N terminale (NT-proBNP) nei pazienti con amiloidosi AL e insufficienza renale 49
Totale 6.028
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.397
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.397
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.413 695 984 1 91 9 94 33 100 9 224 95 78
2020/20211.075 124 85 31 101 7 131 16 192 85 147 126 30
2021/20221.102 21 10 26 11 32 19 11 91 61 42 155 623
2022/20233.826 436 278 47 286 351 350 24 211 1.690 20 85 48
2023/20241.412 181 304 48 109 126 295 33 86 12 43 100 75
2024/20254 4 0 0 0 0 0 0 0 0 0 0 0
Totale 11.111